Latest developments in the field of neurotransmitters

C. Chapple, R. Chess-Williams

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Receptors involved in neurotransmission are an important target for drug therapy and the identification and development of receptor-specific compounds is an essential part of contemporary drug development. Antagonists acting at detrusor muscarinic receptors and prostatic adrenergic receptors are now established therapies for the treatment of bladder instability and benign prostatic hyperplasia, respectively. Future developments await the results of basic pathophysiological studies to establish the role of classical and non-adrenegic, noncholinergic neurotransmission in the development and maintenance of diseases of the lower urinary tract. With the development of better pharmacological tools and molecular biological techniques, receptor properties are likely to be found to be tissue-specific, making the development of drugs with true tissue specificity and fewer side effects a reality.

Original languageEnglish
Pages (from-to)45-47
Number of pages3
JournalEuropean Urology
Volume34
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 22 Sep 1998
Externally publishedYes

Fingerprint

Synaptic Transmission
Neurotransmitter Agents
Urologic Diseases
Organ Specificity
Prostatic Hyperplasia
Muscarinic Receptors
Pharmaceutical Preparations
Adrenergic Receptors
Urinary Bladder
Maintenance
Pharmacology
Drug Therapy
Therapeutics

Cite this

Chapple, C. ; Chess-Williams, R. / Latest developments in the field of neurotransmitters. In: European Urology. 1998 ; Vol. 34, No. SUPPL. 1. pp. 45-47.
@article{af8bef37fbf14267bc5634c364cc41a3,
title = "Latest developments in the field of neurotransmitters",
abstract = "Receptors involved in neurotransmission are an important target for drug therapy and the identification and development of receptor-specific compounds is an essential part of contemporary drug development. Antagonists acting at detrusor muscarinic receptors and prostatic adrenergic receptors are now established therapies for the treatment of bladder instability and benign prostatic hyperplasia, respectively. Future developments await the results of basic pathophysiological studies to establish the role of classical and non-adrenegic, noncholinergic neurotransmission in the development and maintenance of diseases of the lower urinary tract. With the development of better pharmacological tools and molecular biological techniques, receptor properties are likely to be found to be tissue-specific, making the development of drugs with true tissue specificity and fewer side effects a reality.",
author = "C. Chapple and R. Chess-Williams",
year = "1998",
month = "9",
day = "22",
doi = "10.1159/000052277",
language = "English",
volume = "34",
pages = "45--47",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "SUPPL. 1",

}

Latest developments in the field of neurotransmitters. / Chapple, C.; Chess-Williams, R.

In: European Urology, Vol. 34, No. SUPPL. 1, 22.09.1998, p. 45-47.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Latest developments in the field of neurotransmitters

AU - Chapple, C.

AU - Chess-Williams, R.

PY - 1998/9/22

Y1 - 1998/9/22

N2 - Receptors involved in neurotransmission are an important target for drug therapy and the identification and development of receptor-specific compounds is an essential part of contemporary drug development. Antagonists acting at detrusor muscarinic receptors and prostatic adrenergic receptors are now established therapies for the treatment of bladder instability and benign prostatic hyperplasia, respectively. Future developments await the results of basic pathophysiological studies to establish the role of classical and non-adrenegic, noncholinergic neurotransmission in the development and maintenance of diseases of the lower urinary tract. With the development of better pharmacological tools and molecular biological techniques, receptor properties are likely to be found to be tissue-specific, making the development of drugs with true tissue specificity and fewer side effects a reality.

AB - Receptors involved in neurotransmission are an important target for drug therapy and the identification and development of receptor-specific compounds is an essential part of contemporary drug development. Antagonists acting at detrusor muscarinic receptors and prostatic adrenergic receptors are now established therapies for the treatment of bladder instability and benign prostatic hyperplasia, respectively. Future developments await the results of basic pathophysiological studies to establish the role of classical and non-adrenegic, noncholinergic neurotransmission in the development and maintenance of diseases of the lower urinary tract. With the development of better pharmacological tools and molecular biological techniques, receptor properties are likely to be found to be tissue-specific, making the development of drugs with true tissue specificity and fewer side effects a reality.

UR - http://www.scopus.com/inward/record.url?scp=0031655705&partnerID=8YFLogxK

U2 - 10.1159/000052277

DO - 10.1159/000052277

M3 - Article

VL - 34

SP - 45

EP - 47

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - SUPPL. 1

ER -